NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO Annual Meeting

NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO Annual Meeting
SAN CARLOS, Calif., May 20 /PRNewswire-FirstCall/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track [...]

Resolvyx Presents Data Demonstrating Potential For Resolvin Therapeutics To Treat Corneal And Retinal Eye Diseases At …

Resolvyx Presents Data Demonstrating Potential For Resolvin Therapeutics To Treat Corneal And Retinal Eye Diseases At …
Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual [...]

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010
Studies and analyses of the Crohn’s Disease (CD) treatment Cimzia® (certolizumab pegol) demonstrating new data will be exhibited at Digestive Disease Week (DDW) 2010, taking place in New Orleans from May 1-5, 2010.
Read more on News-Medical-Net

Long-Term Data on Cimzia(R) (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at Upcoming …

Long-Term Data on Cimzia(R) (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at Upcoming …
Studies and analyses of the Crohnâs Disease treatment Cimzia® demonstrating new data will be exhibited at Digestive Disease Week 2010, taking place in New Orleans from May 1-5, 2010.
Read more on PR Newswire via Yahoo! Finance

Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week

Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
Lexicon Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving poster and oral presentations on results from its Phase 2 clinical study with LX1031 in patients [...]

New Data Suggest Oral Laquinimod May Confer Neuroprotection in Addition to Immunomodulation in the Treatment of …

New Data Suggest Oral Laquinimod May Confer Neuroprotection in Addition to Immunomodulation in the Treatment of …
LUND, SWEDEN–(Marketwire – 04/15/10) – – Enhanced levels of brain derived neurotrophic factor, possibly contributing to neuroprotection, were shown in laquinimod treated multiple sclerosis (MS) patients – Laquinimod significantly reduce demyelination and axonal damage as shown in animal models [...]

New data shows early treatment with etanercept/methotrexate combo can prevent RA progression

New data shows early treatment with etanercept/methotrexate combo can prevent RA progression
New data from the COMET trial, published in Arthritis & Rheumatism,demonstrate that combination therapy with etanercept and methotrexate over two years achieved radiographic remission (i) in 90 per cent of evaluable subjects with early active rheumatoid arthritis (RA), (1) The results also showed that [...]